KPRX - Kiora Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

KPRX

KIORA PHARMACEUTICALS, INC.

NASDAQ

$2.62

▼ DOWN 1.50% (-0.04)

KEY STATISTICS

Market Cap$11.61 M

52w High$2.95

52w Low$1.76

Dividend Yield—

Frequency—

P/E-1.04

Volume2.28K

Shares Out.4.43M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Brian Strem

COMPENSATION 2026

Salary$489,558

Stock Awards$67,986

Incentive Plan Pay$0

All Other Comp.$2,894

Total$954,883

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 13, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2024-06-11	Reverse	1:9
2022-09-27	Reverse	1:40
2019-08-30	Reverse	1:15

PRICE

$2.62 ▼ DOWN 1.50% (−$0.04)

OVERLAYS

About Kiora Pharmaceuticals, Inc.

https://www.kiorapharma.com ↗

Kiora Pharmaceuticals, a clinical-stage company based in Utah, develops ophthalmic therapies including KIO-301, KIO-101, and KIO-201, targeting vision restoration and eye diseases across various stages of clinical trials.

INDUSTRY

Biotechnology

A PRODUCT KIORA PHARMACEUTICALS, INC. IS KNOWN FOR

KIO-301

KIO-301 is a clinical-stage molecular photoswitch aimed at restoring vision in inherited retinal diseases by enabling retinal ganglion cells to sense light, potentially serving as a first-in-class treatment for patients with minimal or no light pe...